

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO					Complete if Known	
THIRD SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>					Application Number	10/761,435
					Filing Date	January 22, 2004
					First Named Inventor	UMAÑA, Pablo
					Art Unit	1633
					Examiner Name	Burkhart, Michael D.
Sheet	1	of	1	Attorney Docket Number	1975.0180003/TJS/T-M/M-N	

[illegible]

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)				
	FP6	WO 02/000879 A2	01/03/2002	Glycofi, Inc.		
	FP7	WO 02/079255 A1	10/10/2002	Idec Pharmaceuticals Corporation		
	FP8	WO 03/078614 A2	9/25/2003	Plant Research International B.V.		
	FP9	WO 2004/074499 A2	09/02/2004	Gerngross, T. U. <i>et al.</i>		

1082659v1

Examiner Signature	/Michael Burkhardt/	Date Considered	01/17/2011
-----------------------	---------------------	--------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Substitute for form 1449/PTO			Complete if Known		
THIRD SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			Application Number	10/761,435	
			Filing Date	January 22, 2004	
			First Named Inventor	UMANA, Pablo	
			Art Unit	1633	
			Examiner Name	Burkhart, Michael D.	
Sheet	1	of	2 2	Attorney Docket Number	1975.0180003/TJS/T-M/M-N

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	NPL83	MALAISE, M.G., <i>et al.</i> , "In vitro studies on the Fc-receptor function of mononuclear phagocytes in rheumatoid arthritis: Relation between the Fc-receptor blockade and the concanavalin A-binding capacity of autologous immunoglobulin G," <i>J. Clin. Immunol.</i> , 6(6):442-456, Springer, Netherlands (1986)	
	NPL84	MISAGO, M., <i>et al.</i> , "Molecular cloning and expression of cDNAs encoding human alpha-mannosidase II and a previously unrecognized alpha-mannosidase II ^x isozyme," <i>Proc. Natl. Acad. Sci.</i> , 92:11766-11770, National Academy of Sciences, United States (1995)	

1105522_1.DOC

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /MB/

Examiner Signature	/Michael Burkhart/	Date Considered	01/17/2011
-----------------------	--------------------	--------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.